Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics

Siyan Liao1, Kai Tan2, Cecilia Floyd3

  • 1Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China; College of Science and Mathematics, Rowan University, Glassboro, NJ 08028, USA.

Life Sciences
|January 14, 2021
PubMed

Insights

PZM21, a biased agonist, preferentially activates the mu-opioid receptor (MOR) G protein pathway over the β-arrestin pathway. Molecular dynamics simulations reveal PZM21 binding induces conformational changes facilitating G protein interaction, potentially reducing side effects.

Area of Science:

  • Pharmacology
  • Structural Biology
  • Computational Chemistry

Background:

  • Morphine, a mu-opioid receptor (MOR) agonist, treats pain but causes side effects via β-arrestin pathway activation.
  • PZM21 is a novel MOR-biased agonist designed to favor G protein signaling over β-arrestin signaling.

Purpose of the Study:

  • To elucidate the molecular mechanism of PZM21 action at the MOR.
  • To compare PZM21 and morphine binding and activation dynamics.

Main Methods:

  • Molecular docking of PZM21 and morphine to a human MOR homology model.
  • Molecular dynamics (MD) simulations with and without crystal waters.
  • Analysis of protein-ligand interactions, structural dynamics, and signaling pathways.

Main Results:

  • PZM21 strongly interacts with MOR residues Y328(7.43), Asp149(3.32), and Tyr150(3.33).
  • PZM21 binding causes outward bending of MOR intracellular TM5-7 helices, distinct from morphine.
  • Simulation results suggest PZM21 binding creates a larger intracellular cavity, potentially enhancing G protein coupling.

Conclusions:

  • PZM21's biased agonism is structurally supported by distinct MOR conformational changes.
  • The observed structural dynamics provide insights into PZM21's preferential G protein pathway activation.
  • This study offers a structural basis for developing safer analgesics targeting the MOR.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.2K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.2K
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.8K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.4K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
6.9K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.4K